CytoAgents' CTO1681 and CRS
Calming the Cytokine Storm
Cytokine Release Syndrome (CRS) Overview
Cytokine Release Syndrome (CRS) is an overreaction of the immune system caused by excessive prolonged cytokine production, leading to systemic inflammation, often referred to as the Cytokine Storm.
The condition can be triggered by a wide range of indications, such as cancer cell therapy, autoimmune disorders, and traumatic brain injury, as well as viral and bacterial infections.
CRS occurs when the body mounts an excessive and uncontrolled response to a disease or trauma. Left unchecked, CRS leads to systemic inflammation, which can result in shock, multiple organ failure, and death.
CRS occurs when the body does not adequately modulate cytokine production in the wake of an inflammatory response by the immune system. The amplification of cytokines result in the cytokine storm spiraling out of control, causing the immune system to attack and damage healthy cells, tissues, and organs. CRS can often be more damaging to patient health than the triggering disease itself.
Modulating and Rebalancing the Immune System
Cytokines play a critical role in enabling the immune system to protect the body from diseases and other sources of potential injury. Immune cells produce cytokines to activate and recruit other immune cells to help eliminate threats; these immune cells in turn produce their own cytokines to amplify this signal, recruiting more cells and creating a feedback loop resulting in a targeted inflammatory response. Normally, the body balances this inflammatory response with a series of anti-inflammatory measures which down regulate the production of cytokines thereby restoring homeostasis. In the absence of adequate negative regulation, cytokine production and activation can spiral out of control, causing excessive systemic inflammation and leading to the dangerous condition of Cytokine Release Syndrome (CRS).
CytoAgents’ approach to treatment focuses on rebalancing the immune system by reducing the destructive impact of excessive cytokines, while leaving necessary immune functions intact.
CytoAgents and CRS
CytoAgents lead drug candidate, CTO1681, activates the immune cells’ natural signaling pathway for down regulating the production of a broad range of cytokines. CTO1681 dramatically reduces, without eliminating, cytokine production by immune cells, rebalancing the immune response while leaving its necessary functions intact. This novel approach has certain advantages over other treatments strategies, namely:
- CTO1681 affects a broad range of cytokines, therefore is less likely to be circumvented by redundant signaling pathways
- CTO1681 can be used not only to treat CRS, but also to prevent it from occurring
- CTO1681 is a small molecule treatment, which offers cost-advantages and a broader range of delivery options